4yff: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
← Older edit
No edit summary
No edit summary
 
Line 4: Line 4:
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[4yff]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4YFF OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4YFF FirstGlance]. <br>
<table><tr><td colspan='2'>[[4yff]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4YFF OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4YFF FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4CV:3-[(5-BROMO-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]-N-METHYL-4-(MORPHOLIN-4-YL)BENZENESULFONAMIDE'>4CV</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.07&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4CV:3-[(5-BROMO-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]-N-METHYL-4-(MORPHOLIN-4-YL)BENZENESULFONAMIDE'>4CV</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4yff FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4yff OCA], [https://pdbe.org/4yff PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4yff RCSB], [https://www.ebi.ac.uk/pdbsum/4yff PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4yff ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4yff FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4yff OCA], [https://pdbe.org/4yff PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4yff RCSB], [https://www.ebi.ac.uk/pdbsum/4yff PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4yff ProSAT]</span></td></tr>
</table>
</table>
Line 11: Line 12:
== Function ==
== Function ==
[https://www.uniprot.org/uniprot/TNI3K_HUMAN TNI3K_HUMAN] May play a role in cardiac physiology.<ref>PMID:12721663</ref>  
[https://www.uniprot.org/uniprot/TNI3K_HUMAN TNI3K_HUMAN] May play a role in cardiac physiology.<ref>PMID:12721663</ref>  
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
A series of cardiac troponin I-interacting kinase (TNNI3K) inhibitors arising from 3-((9H-purin-6-yl)amino)-N-methyl-benzenesulfonamide (1) is disclosed along with fundamental structure-function relationships that delineate the role of each element of 1 for TNNI3K recognition. An X-ray structure of 1 bound to TNNI3K confirmed its Type I binding mode and is used to rationalize the structure-activity relationship and employed to design potent, selective, and orally bioavailable TNNI3K inhibitors. Identification of the 7-deazapurine heterocycle as a superior template (vs purine) and its elaboration by introduction of C4-benzenesulfonamide and C7- and C8-7-deazapurine substituents produced compounds with substantial improvements in potency (&gt;1000-fold), general kinase selectivity (10-fold improvement), and pharmacokinetic properties (&gt;10-fold increase in poDNAUC). Optimal members of the series have properties suitable for use in in vitro and in vivo experiments aimed at elucidating the role of TNNI3K in cardiac biology and serve as leads for developing novel heart failure medicines.
Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K).,Lawhorn BG, Philp J, Zhao Y, Louer C, Hammond M, Cheung M, Fries H, Graves AP, Shewchuk L, Wang L, Cottom JE, Qi H, Zhao H, Totoritis R, Zhang G, Schwartz B, Li H, Sweitzer S, Holt DA, Gatto GJ Jr, Kallander LS J Med Chem. 2015 Sep 24;58(18):7431-48. doi: 10.1021/acs.jmedchem.5b00931. Epub, 2015 Sep 10. PMID:26355916<ref>PMID:26355916</ref>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 4yff" style="background-color:#fffaf0;"></div>


==See Also==
==See Also==

Latest revision as of 16:03, 1 March 2024

TNNI3K complexed with inhibitor 2TNNI3K complexed with inhibitor 2

Structural highlights

4yff is a 4 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 3.07Å
Ligands:
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Disease

TNI3K_HUMAN The disease is caused by mutations affecting the gene represented in this entry.

Function

TNI3K_HUMAN May play a role in cardiac physiology.[1]

See Also

References

  1. ↑ Zhao Y, Meng XM, Wei YJ, Zhao XW, Liu DQ, Cao HQ, Liew CC, Ding JF. Cloning and characterization of a novel cardiac-specific kinase that interacts specifically with cardiac troponin I. J Mol Med. 2003 May;81(5):297-304. Epub 2003 Apr 30. PMID:12721663 doi:http://dx.doi.org/10.1007/s00109-003-0427-x

4yff, resolution 3.07Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA
Retrieved from "https://proteopedia.openfox.io/wiki/index.php?title=4yff&oldid=4076744"